MELBOURNE, Fla., April 5, 2011 /PRNewswire/ -- Medicomp Inc., previously a wholly-owned subsidiary of United Therapeutics Corporation, announced today that it has been acquired by an investment group made up of current and past Medicomp management led by Dan Balda, MD, Medicomp's President and CEO. The sale was finalized on March 31, 2011 and will allow the new Medicomp organization to focus on growing the Medicomp brand and business to become the medical monitoring center to the world. United Therapeutics retained a minority stake in the company as part of the sale.
"We are extremely excited about this opportunity to grow Medicomp and better assist physicians in diagnosing and treating cardiac disease. Our independence will enable increased focus so we can quickly add new technology partners, further increase the value we bring to patients, maximize clinically significant results to physicians, and seamlessly integrate into the medical community while injecting cost effectiveness into the healthcare system," stated Dr. Balda.
Medicomp will maintain and grow the current management structure to ensure that Medicomp customers are not impacted in any way by this change.
About Medicomp Inc.
Medicomp Inc (www.medicompinc.com), develops and provides advanced cardiac monitoring products and services using the most sophisticated and reliable ambulatory heart-monitoring systems available. Medicomp's diagnostic technologies are widely regarded as the most advanced in the industry, and they are therefore entrusted by physicians and scientists to provide cardiac monitoring services around the world in healthcare, research as well as space and aeronautical exploration.
Medicomp's cardiac monitors use artificial intelligence operating in real-time. Our proprietary Diogenes algorithm employs rate, rhythm, morphology, and p-wave information for the most comprehensive ECG analysis available.
SOURCE Medicomp, Inc.